An optimal dosing schedule for a novel combination antimetabolite, TAS-102, based on its intracellular metabolism and its incorporation into DNA.
about
Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignanciesPhase I study of TAS-102 treatment in Japanese patients with advanced solid tumours.Prodrug activation by Cryptosporidium thymidine kinase.Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models.Crucial roles of thymidine kinase 1 and deoxyUTPase in incorporating the antineoplastic nucleosides trifluridine and 2'-deoxy-5-fluorouridine into DNA.New challenges and inspired answers for anticancer drug discovery and developmentMechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells.The Hollow Fibre Assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cellsThe antibodies against 5-bromo-2'-deoxyuridine specifically recognize trifluridine incorporated into DNA.TAS-102, a novel antitumor agent: a review of the mechanism of action.TAS-102: a novel antimetabolite for the 21st century.Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts.MicroRNA profiles involved in trifluridine resistance.Simple and rapid enzymatic method for the synthesis of single-strand oligonucleotides containing trifluorothymidine.Trifluorothymidine exhibits potent antitumor activity via the induction of DNA double-strand breaks.DNA replication stress and cancer chemotherapy.Monitoring trifluridine incorporation in the peripheral blood mononuclear cells of colorectal cancer patients under trifluridine/tipiracil medication.Trifluridine/tipiracil overcomes the resistance of human gastric 5-fluorouracil-refractory cells with high thymidylate synthase expression.Effective Sequential Combined Chemotherapy with Trifluridine/Tipiracil and Regorafenib in Human Colorectal Cancer Cells
P2860
Q26777679-09C38F86-C498-493E-8C7B-B9621741579BQ33401982-CE416BE4-FE28-4AC4-B1F6-C1DC4868F5D0Q33855150-DC5DF431-81F1-4612-B43F-0E1A3CE97FA5Q34439214-0BEA8C62-1529-43D1-9FC0-1B7085DEC192Q34473056-0EA21AB4-4761-4FF4-876E-A887502DF470Q34981175-6E0CFD9F-A84D-475C-A6F1-6484F410CB82Q36609769-06AFA20F-A87E-4D2B-973B-FAA1689E8078Q36610507-AD67333F-F1AA-4A7D-B070-C0130492C454Q36860056-919B5785-BC2D-44E4-927B-716001CEB983Q38597310-3A92D81A-6F13-47DC-922A-E5EA31AC1CEBQ38652269-8C8A355C-4FFC-466A-9019-12D7DEED7E70Q38894690-D7DFBFBC-D447-482E-BA6F-D75EEE8B3FA4Q41593018-87D73B1F-5E2D-4E78-B974-A29896233528Q42011930-A9933ABF-659C-4212-9A33-AF159FD6F5FCQ43080247-3A78BD6E-8B3D-470D-8F91-9143D4D47CDFQ48247320-81FBD375-7E34-4381-8D5C-B35FD60B8069Q48580029-D4A3E14F-DF96-4B75-AAC8-E5B1D52A8448Q55006325-3D82EDF6-07E6-4F62-B270-E6B1693BDD44Q59138354-F874154E-D01F-4B33-A937-B4938927BC87
P2860
An optimal dosing schedule for a novel combination antimetabolite, TAS-102, based on its intracellular metabolism and its incorporation into DNA.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
An optimal dosing schedule for ...... nd its incorporation into DNA.
@en
An optimal dosing schedule for ...... nd its incorporation into DNA.
@nl
type
label
An optimal dosing schedule for ...... nd its incorporation into DNA.
@en
An optimal dosing schedule for ...... nd its incorporation into DNA.
@nl
prefLabel
An optimal dosing schedule for ...... nd its incorporation into DNA.
@en
An optimal dosing schedule for ...... nd its incorporation into DNA.
@nl
P2093
P1476
An optimal dosing schedule for ...... and its incorporation into DNA
@en
P2093
Akio Fujioka
Fumio Nakagawa
Hideyuki Ohshimo
Hiroyuki Okabe
Kenji Kitazato
Tatsushi Yokogawa
Tomohiro Emura
P304
P577
2004-02-01T00:00:00Z